Angiotensin-converting enzyme (ACE), CSF-13383

Test info

  
Angiotensin-converting enzyme (ACE), CSF
  
13383
  
LAB13383
  
ACEC
  
ACE
Angiotensin converting enzyme (ACE), cerebrospinal fluid
  

Quantitative measurement of ACE in CSF

Specimen

  
Cerebrospinal fluid (CSF)
  
0.5 mL
  
0.2 mL
  

Sterile plastic vial/tube

  

Ambient (preferred) - 14 days

Refrigerated - 14 days

Frozen - 14 days

Freeze/thaw cycle: stable x3

 

  
  • Hemolysis

Performance

  
LabCorp Burlington (123231): R-LC
  
Mo - Fr
  
3 - 5 days
  

Quantitative spectrophotometry

Clinical and Interpretive info

  

0 - 5 years:     Not established

6 - 17 years:   0.0 - 2.1 U/L

18 - 50 years: 0.0 - 2.5 U/L

> 50 years:     0.0 - 3.1 U/L

  

Angiotensin Converting Enzyme (ACE) is used in the assessment of neurosarcoidosis. The major sources of ACE are macrophages and epithelial cells. Patients with sarcoidosis display elevated levels of ACE.

Angiotensin-converting enzyme catalyzes the formation of angiotensin II by cleaving the C-terminal histidylleucine dipeptide from angiotensin I. Indications are that ACE is affiliated with an autonomous renin-angiotensin system of the brain that participates in physiologic processes inside the brain. Also, studies suggest that changes in ACE concentrations in brain tissue, caused by various neurologic disorders, are reflected by alterations in ACE activity in cerebrospinal fluid (CSF). Increased ACE concentrations in CSF are associated with neurosarcoidosis, with affected patients generally having activities approximately two-fold or more higher than those of healthy individuals. Increased CSF ACE has also been implicated in neurologic diseases, such as bacterial and viral meningitis and Behcet disease. Decreased concentrations have been reported in patients with Alzheimer disease, Parkinson disease, and progressive supranuclear palsy.

Billing

  
82164
  
Result 12480-0

Tracking

  
03/27/2019
  
03/29/2021
  
02/12/2021